It is now well recognized that ATP and other nucleotides act as extracellular signalling molecules to induce a variety of cellular responses by interacting with specific cell-surface receptors known as P2-purinoceptors (Gordon, 1986; Harden et al, 1995) . The diversity of cellular responses to ATP and other nucleotides (Dubyak and Fedan, 1990; El-Moatassim et al, 1992) suggested the involvement of multiple receptor types, and the classification of receptor subtypes was originally inferred from pharmacological responses to nucleotides in vitro (Burnstock and Kennedy, 1985) .
Two major classes of P2-purinoceptors have been delineated: P2X purinoceptors, which are ligand-gated ion channels, and P2Y purinoceptors, which are G-protein-coupled receptors. This classification has recently been expanded (Abbracchio and Burnstock, 1994; Barnard et al, 1994) to accommodate the results of cloning studies that revealed the existence of multiple subclasses of P2y purinoceptors Webb et al, 1993; Parr et al, 1994) . Activation of the two major subclasses of G-proteincoupled receptors, P2Y(P2Y1) and P2U(P2Y2)' results in phospholipase C-catalysed hydrolysis of phosphatidylinositol 4,5-bisphosphate and consequent inositol 1,4,5-trisphosphate-mediated release of calcium from intracellular stores (Boarder et al, 1995) . A large number of studies have demonstrated the existence of G-proteincoupled P2-purinoceptors on tumour cell lines (Dubyak, 1986; Dubyak et al, 1988; Gonzalez et al, 1989a,b; El-Moatassim et al, 1992; Torres-Marquez et al, 1993) , but the implications of purinergic stimulation for the growth and development of cancer have not been thoroughly investigated, as studies of growth control of tumours have tended to focus on peptide growth factors and hormones. A number of investigators have demonstrated inhibition of cancer cell growth by ATP at high concentrations (100 gM to 1 mM) (Weisman et al, 1988; Rapaport, 1990; Dubyak and El-Moatassim, 1993) . At lower concentrations, however, mitogenic actions of extracellular ATP, mediated by P2-purinoceptors, have been reported in numerous cell types, including aortic smooth muscle cells (Wang et al, 1992) , mesangial cells (SchulzeLohoff et al, 1992; Ishikawa et al, 1994) and the human ovarian cancer cell lines, OVCAR-3 (Popper and Batra, 1993) and SKOV-3 (Batra and Fadeel, 1994) . ATP has also been shown to act as a co-mitogen in concert with other growth factors to enhance cellular proliferation in transformed mouse fibroblasts and epidermoid carcinoma A431 cells (Huang et al, 1989) and aortic smooth muscle (Wang et al, 1992) .
We have recently cloned the human P2U purinoceptor from a human giant cell tumour (osteoclastoma) (Bowler et al, 1995) , The presence of P2U purinoceptors on these and other tumour cells has led us to consider the possibility that these receptors might be important in the growth or progression of the tumour. In the current study, we have analysed the expression of P2U purinoceptors in human breast cancer cell lines. In one of these lines (MCF-7), we have studied the effects of ATP and other purinergic agonists on intracellular free calcium concentration ([Ca2+] ,) and on cell proliferation. We have previously demonstrated proliferative effects of parathyroid hormone-related protein (PTHrP) on MCF-7 cells . A synergistic interaction between parathyroid hormone (PTH) and ATP on [Ca2+], has been described in rat osteoblasts (Kaplan et al, 1995) . As PTHrP binds to the same receptor as PTH, we have studied the effects of PTHrP, alone and in concert with nucleotides, on MCF-7 cells.
MATERIALS AND METHODS Cell culture
Breast cancer cell lines MCF-7, Hs578T, T47-D and SK-Br3 were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U ml-penicillin, 100 jig ml-' streptomycin and 2 mM L-glutamine (all reagents from Gibco). Cultures were incubated at 37°C in a fully humidified atmosphere of 7.5% carbon dioxide in air, and subcultured every 3-5 days.
[Ca2+], measurement MCF-7 cells were grown to confluence on 22-mm-diameter glass coverslips. Following 2 h of serum starvation, [Ca2+]i was measured. Cells were loaded with fura-2 by incubation with fura-2 acetoxymethyl ester (5 jM) (Molecular Probes) for 20 min at 37°C in Hepes buffer (10 mM Hepes, 121 mm sodium chloride, 4.7 mM potassium chloride, 1.2 mm potassium hydrogen phosphate, 1.2 mM magnesium sulphate, 2 mm calcium chloride, 5 mM sodium hydrogen carbonate, 10 mM glucose, pH 7.2) containing 2% bovine serum albumin (BSA). Cells were subsequently washed three times in buffer of the same composition but containing 0.2% BSA.
Experiments were carried out using a photon-counting spectrophotometer (Cairn Instruments) on a Nikon TM Diaphot microscope with a 40x oil immersion lens. The cell-coated coverslip was attached with silicone grease to form the base of a stage-mounted, thermostatically regulated chamber maintained at 37°C. An area of the coverslip encompassing approximately 6-8 cells was illuminated with excitation light (340 nm and 380 nm) at a rate of 32 times per second, and the emission measurements (at 510 nm) were integrated into 1-s averages, then stored to memory. Addition of agonists, in Hepes buffer with 0.2% BSA, was performed manually by Pasteur pipette, and recovery periods of at least 10 min were allowed between agonist additions. Rmmn' Rmax and autofluorescence values were obtained in situ using ionomycin, as described by Thomas and Delaville (1991) . [Ca2+] was calculated from the ratio of fluorescence at the two excitation wavelengths, after subtraction of autofluorescence (Grynkiewicz et al, 1985) .
RNA isolation and cDNA synthesis
Total RNA was extracted from confluent cell cultures with 4 M guanidine thiocyanate, 0.5% sarkosyl, 0.1 M mercaptoethanol, 25 mm sodium citrate, pH 7.0, followed by acid phenol -chloroform [3H] thymidine together with the substance (e.g. ATP) to be tested for effects on proliferation, was then added to each well. Following 24 h of incubation, the medium was removed and replaced with distilled water, the plates were frozen and thawed to lyse the cells and the wells were harvested onto glass-fibre filters using a cell harvester and [3H]thymidine incorporation measured on a scintillation counter.
Cell counting MCF-7 cells were seeded at 2 x 104 cells per well in 0.5 ml of DMEM/10% FCS in 24-well plates and allowed to adhere overnight in culture. The medium was changed to serum-free DMEM and the cells were incubated for 24 h. ATPyS and/or PTHrP was then added at the appropriate concentration and the plates incubated for a further 72 h. At the end of this period, the medium was removed, the wells were washed in phosphatebuffered saline (PBS) and 300 jil of 0.25% trypsin/EDTA solution (Table 1) .
PTHrP, which we have previously shown to provide a proliferative stimulus for MCF-7 cells , did not induce any increase in [Ca2+], (Figure 4 ).
ATPyS stimulates proliferation of MCF-7 cells
To investigate the potential effects of ATP on proliferation, ATPyS was used, as indicated above. Proliferation was analysed by three methods, uptake of [3H]thymidine, incorporation of BUdR and counting of total cell numbers. By all three methods, micromolar concentrations of ATPyS were shown to provide a proliferative stimulus for MCF-7 cells. Thymidine incorporation by serumstarved MCF-7 cells was approximately doubled in the presence of 5 gM ATPyS compared with controls ( Figure 5 ). Increasing the concentration of ATPyS to 50 gM or 500 gM did not produce any further rise above that seen with 5 ,UM ATPyS. Similarly, the numbers of nuclei staining positively for BUdR uptake more than doubled in the presence of 10 gM ATPyS (Table 2 ). When total cell numbers were counted, a similar pattern emerged. Whereas serumstarved MCF-7 cells showed little or no increase in cell number after a further 3 days in serum-free medium, the addition of ATPyS (10 gM) to the medium on a daily basis resulted in a doubling of cell numbers after 3 days (Figure 6 ). PTHrP also increased cell numbers, and when ATPyS (10 ,UM) and PTHrP (100 ng ml-') were applied together, an additive effect was seen in the cell-counting assay, although not in the BUdR assay. This suggests that ATP (ATPyS) and PTHrP may act via different pathways in MCF-7 cells, which is consistent with the finding shown in Figure 4, where PTHrP, unlike ATP, did not evoke a rise in [Ca2+] i. P2T (P2Y3) purinoceptors, respectively, for which these nucleotides are agonists (Barnard et al, 1994 (Batra and Fadeel, 1994) . Similarly high concentrations of ATP were reported to induce growth inhibition in two breast cancer cell lines, T47-D (Spungin and Friedberg, 1993) and that used here, MCF-7 (Vandewalle et al, 1994) . The mechanism underlying this inhibition is not fully understood. Some investigators have attributed inhibition to adenosine following the sequential dephosphorylation of ATP (Spungin and Friedberg, 1993; Lasso de la Vega et al, 1994) , whereas others have invoked P2Z purinoceptormediated cell permeabilization (Rapaport, 1990; Dubyak and ElMoatassim, 1993) . Considering the high concentrations of ATP required to achieve this effect, its physiological relevance is questionable. We have not observed any inhibition of cell growth in response to ATPyS at concentrations up to 100 gM, which may be a result of using this slowly hydrolysable analogue of ATP. The response of tumour cells to growth factors and other agents is dependent on the range of receptors expressed by the cells. The expression of P2U purinoceptors by breast cancer cells indicates that ATP must be considered as a potential regulatory factor in cancer cell growth. In concert with other factors, the mitogenic stimulus provided by ATP could be sufficient to drive tumour growth or progression in vivo. One such factor could be PTHrP, (Vargas et al, 1992) , whereas potential sources of high local ATP concentrations would include any condition in which cells are being lysed, including ischaemia and necrosis, inflammation or specific lysis by cytotoxic or NK cells.
These data implicate nucleotides and their receptors either alone or in combination with other tumour-stimulatory factors as possible regulators of tumour cell growth and as potential therapeutic targets for inhibiting tumour progression.
